ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

We recently published a list of Why These 10 Stocks Soared by Double Digits Today. In this article, we are going to take a ...

Cardiff Oncology is entering a pivotal stage with a strong cash runway and compelling early data in first-line RAS-mutant ...

Beyond the major indices, 10 companies finished the week stronger, booking double-digit gains during the day. In this article ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...